| Disease |
| Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
| hepatocelluar carcinoma |
microarray, qPCR etc. |
HCC tissue |
up-regulated |
N/A |
The results showed that BC017743, ENST00000395084, NR_026591, NR_015378 and NR_024284 were up-regulated and NR_027151, AK056988 and uc003yqb.1 were down-regulated in HCC samples compared with adjacent NT samples. |
25025236 |
Lnc2Cancer
|
| hepatocelluar carcinoma |
microarray, qPCR, knockdown etc. |
HCC tissue, cell lines (Huh7, HepG2, etc.) |
up-regulated |
interaction |
We found that ZEB1-AS1 is frequently upregulated in HCC samples, especially in metastatic tumor tissues. ZEB1-AS1 promotes tumor growth and metastasis, acts as an oncogene in HCC. The ZEB1-AS1 gene is located in physical contiguity with ZEB1 and positively regulates the ZEB1 expression. ZEB1 inhibition partially abrogates ZEB1-AS1-induced epithelial to mesenchymal transition (EMT) and cancer metastasis. |
26073087 |
Lnc2Cancer
|
| esophageal squamous cell carcinoma |
qPCR etc. |
ESCC tissues and adjacent non-tumor tissues |
up-regulated |
expression |
LNCRNA ZEB1-AS1 was found up-regulated in ESCC tissues compared to adjacent non-tumor tissues. Increased lncRNA ZEB1-AS1 expression was significantly associated with tumor grade, depth of invasion, and lymph node metastasis. Kaplan-Meier analysis revealed that ESCC patients with high ZEB1-AS1 expression had a poorer overall survival and disease-free survival. Furthermore, multivariate analysis suggested that ZEB1-AS1 expression was identified as an independent prognostic factor in patients with ESCC |
26617942 |
Lnc2Cancer
|
| |